The invention describes novel substituted aryl compounds that are
cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions
comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and,
optionally, at least one compound that donates, transfers or releases
nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates
endogenous levels of endothelium-derived relaxing factor or is a substrate
for nitric oxide synthase, and/or, optionally, at least one therapeutic
agent, such as, steroids, nonsterodal antiinflammatory compounds (NSAID),
5-lipoxygenase (5-LO) inhibitors, leukotriene B.sub.4 (LTB.sub.4) receptor
antagonists, leukotriene A.sub.4 (LTA.sub.4) hydrolase inhibitors, 5-HT
agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors,
H.sub.2 antagonists, antineoplastic agents, antiplatelet agents, thrombin
inhibitors, thromboxane inhibitors, decongestants, diuretics, sedating or
non-sedating anti-histamines, inducible nitric oxide synthase inhibitors,
opioids, analgesics, Helicobacter pylori inhibitors, proton pump
inhibitors, isoprostane inhibitors, and mixtures thereof. The invention
also provides novel kits comprising at least one COX-2 selective
inhibitor, and, optionally, at least one nitric oxide donor, and/or,
optionally, at least one therapeutic agent. The novel cyclooxygenase 2
selective inhibitors of the invention can be optionally nitrosated and/or
nitrosylated. The invention also provides methods for treating
inflammation, pain and fever; for treating and/or improving the
gastrointestinal properties of COX-2 selective inhibitors; for
facilitating wound healing; for treating and/or preventing renal toxicity
or other toxicities; for treating and/or preventing other disorders
resulting from elevated levels of cyclooxygenase-2; and for improving the
cardiovascular profile of COX-2 selective inhibitors.
A invenção descreve os compostos aryl substituídos novela que são cyclooxygenase 2 (COX-2) inibidores e composições seletivos da novela que compreendem ao menos um inibidor seletivo do cyclooxygenase 2 (COX-2), e, opcionalmente, ao menos o um composto que doa, transfere ou libera o óxido nitric, estimula a síntese endogenous do óxido nitric, elevates níveis endogenous do fator relaxando endothelium-derivado ou é uma carcaça para o synthase nitric do óxido, e/ou, opcionalmente, ao menos um agente therapeutic, como, steroids, compostos antiinflammatory nonsterodal (NSAID), (5-LO) inibidores 5-lipoxygenase, antagonistas do receptor do leukotriene B.sub.4 (LTB.sub.4), inibidores do hydrolase do leukotriene A.sub.4 (LTA.sub.4), 5-HT agonists, 3-hydroxy-3-methylglutaryl o coenzyme Inibidores de A (HMG-CoA), H.sub.2 antagonistas, agentes antineoplastic, agentes do antiplatelet, inibidores do thrombin, inibidores do thromboxane, decongestants, diuretics, sedating ou non-non-sedating anti-histamines, inibidores nitric inducible do synthase do óxido, opioids, analgesics, de pylori de Helicobacter inibidores, inibidores da bomba do proton, inibidores do isoprostane, e misturas disso. A invenção fornece também os jogos da novela que compreendem ao menos um inibidor COX-2 seletivo, e, opcionalmente, ao menos um doador nitric do óxido, e/ou, opcionalmente, ao menos um agente therapeutic. O cyclooxygenase que da novela 2 inibidores seletivos da invenção podem ser opcionalmente nitrosated e/ou nitrosylated. A invenção fornece também métodos tratando o inflammation, a dor e a febre; para tratar e/ou melhorar as propriedades gastrointestinal dos inibidores COX-2 seletivos; para facilitar a ferida que healing; para tratar e/ou impedir o toxicity renal ou os outros toxicities; para tratar e/ou impedir outros disorders resultando dos níveis elevated de cyclooxygenase-2; e para melhorar o perfil cardiovascular dos inibidores COX-2 seletivos.
